Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Webcast

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences


Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:

Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.


These press releases may also interest you

at 20:07
Ascentage Pharma Received US$100 Million Option Payment from Takeda
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

at 20:00
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...

at 19:54
British Columbia designates Psychotherapy under the Health Professions Act
On July 02, 2024, the BC Government designated Psychotherapy as a Health Profession under the Health Professions Act. The proposal received cabinet approval and was subsequently signed by the Lieutenant Governor. The official order can be viewed...

at 19:52
Whitman-Walker Institute Condemns Nationwide Injunction Blocking Federal Nondiscrimination Protections for Transgender People Following a 'Shameful' Decision in Tennessee Case
Whitman-Walker Institute condemns the politically motivated ruling from a federal district court judge that blocks vital nondiscrimination protections for transgender people across the country. Today, a U.S. district court judge in Mississippi issued...

at 19:22
Baixiang brand Instant Noodles recalled due to undeclared peanut
Product: Instant Noodle Issue: Food - Allergen - Peanut Distribution: AlbertaBritish ColumbiaOntario See the affected products and product photos for this recall Company information Five Continents International Ltd. Telephone: 416-292-6766| Fax:...

at 18:45
Samaritan's Purse Airlifts Relief Supplies to Hurricane-Battered Grenada
The Samaritan's Purse DC-8 departed our hangar in Greensboro, North Carolina, yesterday morning, with a 13-member Disaster Assistance Response Team (DART) and 24 tons of life-saving relief for hurricane-devastated residents of Grenada in the south...

More news about Health...


News published on and distributed by: